Long-term safety and effectiveness of ruxolitinib in Japanese patients with polycythemia vera: a post-marketing study.

ABSTRACT:

Aim

This study evaluated the long-term safety and effectiveness of ruxolitinib in Japanese patients with polycythemia vera in clinical practice.

Patients and methods

This multicenter, single-arm, non-interventional, prospective, observational study assessed patients receiving ruxolitinib after approval.

Results

Of 550 patients (median age: 71 years, mean disease duration: 5.43 years, median treatment duration: 1091 days), 51.27% reported adverse drug reactions (ADRs) and 12.18% had serious ADRs, with anemia being the most common ADR. The highest incidence of ADRs (40%) was observed from treatment initiation to Day 182, with no tendency for increased incidence thereafter. ADRs of special interest included myelosuppression (27.64%), hepatic impairment (13.45%), infectio

SUBMITTER: Hayashi T 

PROVIDER: S-EPMC12758285 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature